Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
R Liévin, B Burroni, E Balducci, P Palmic, J Decroocq, B Deau-Fischer, P Franchi, M Vignon, J Zerbit, A S Cottereau, A Touzart, P Villarese, S Kaltenbach, L Lhermitte, V Asnafi, D Bouscary, L Willems
Primary testicular lymphoma (PTL) is a rare occurrence of diffuse large B-cell lymphoma (DLBCL) that accounts for 1%-2% of all cases. Nodal DLBCL with testis involvement (DLBCL-T) and PTL are associated with poor prognosis, with high incidence of central nervous system relapse. Fifteen patients (median age 60 years) with PTL (n = 5) or DLBCL-T (n = 10) received high-dose methotrexate + R-CHOP. Overall, complete response (CR) rate was 73% and overall response rate 86%...
October 12, 2024: European Journal of Haematology
#2
JOURNAL ARTICLE
Cecilie Maria Lüthje Clausen, Eva Funding, Anders Tolver, Mary Jarden
BACKGROUND: New treatments for patients with bleeding disorders (PWB) have emerged, including products with extended half-life and subcutaneous administration. These less frequent treatments can potentially enhance quality of life (QoL), but adherence becomes critically important. AIM: To investigate adherence and QoL among PWB and explore the correlation between treatment adherence and QoL in adult patients with haemophilia A (HA), haemophilia B (HB) and Von Willebrand disease (vWD) in Denmark...
October 10, 2024: European Journal of Haematology
#3
REVIEW
Akshata Pahelkar, Deep Sharma, Payaam Vohra, Sayli Sawant
Hemoglobin H (HbH) disease, a form of alpha-thalassemia, poses significant clinical challenges due to its complex molecular underpinnings. It is characterized by reduced synthesis of the alpha-globin chain. The integration of multi-omics and precision medicine holds immense potential to comprehensively understand and capture interactions at the molecular and genetic levels. This review integrates current multi-omics approaches and advanced technologies in HbH research. Furthermore, it delves into detailed pathophysiology and possible therapeutics in the upcoming future...
October 9, 2024: European Journal of Haematology
#4
JOURNAL ARTICLE
Brigid Jacob, Maria Jamil, Shahm Raslan, Kylie Springer, Zeinab Nasser, Philip Kuriakose
Prior to the national shortage of iron dextran in early 2023, it was the most commonly administered intravenous iron infusion at our institution. After the shortage impacted the health system, alternatives such as iron sucrose and sodium ferric gluconate/sucrose were required that utilized lower doses given at more frequent patient visits. Coinciding with their more prevalent use, an increase in iron infusion reactions was observed. Our study analyzed 880 patients who received iron infusions in three Henry Ford Hospital clinics in metropolitan Detroit, Michigan, from July 2022-June 2023...
October 9, 2024: European Journal of Haematology
#5
JOURNAL ARTICLE
Reduced Intensity Conditioning Prior Autologous Stem Cell Transplantation in Elderly DLBCL Patients.
Tim Strüßmann, Philipp Hermes, Gabriele Ihorst, Jürgen Finke, Jesús Duque-Afonso, Monika Engelhardt, Justus Duyster, Reinhard Marks
High-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) is widely used in patients with diffuse large B-cell lymphoma. HDCT/ASCT is associated with increased morbidity in elderly/unfit patients. We retrospectively evaluated the use of reduced intensity conditioning in DLBCL patients. Our study included 146 patients aged 60 years and older treated at our institution between 2005 and 2019; 86 patients received standard intensity conditioning (SI group) with BEAM or TEAM (BCNU or thiotepa, etoposide, cytarabine, melphalan)...
October 9, 2024: European Journal of Haematology
#6
JOURNAL ARTICLE
Honar Cherif, Qian Cai, Concetta Crivera, Ann Leon, Iffat Rahman, Amy Leval, Wim Noel, Christian Kjellander
OBJECTIVES: Warm autoimmune hemolytic anemia (wAIHA) is a rare autoantibody-mediated disorder, and first-line treatment primarily relies on corticosteroids. This study assessed overall survival (OS) and treatment patterns of wAIHA in Sweden. METHODS: Adults with ≥ 1 primary diagnosis code for wAIHA (or AIHA plus oral corticosteroids (OCS)/immunosuppressants as sensitivity analyses) between 2011 and 2022 were identified from five Swedish national registers and linked through each patient's unique identity number...
October 9, 2024: European Journal of Haematology
#7
JOURNAL ARTICLE
Ji-Gan Wang, Hui-Hong Dou, Qiong-You Liang
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder, and recent research suggests that gut microbiota and inflammatory cytokines may play a significant role in its pathogenesis. However, the specific effects of these factors on ITP and their relationships remain unclear. We conducted a two-step, two-sample Mendelian randomization study using an inverse variance-weighted approach to investigate the causal role of the gut microbiota in ITP and the mediating effect of inflammatory cytokines on their association...
October 8, 2024: European Journal of Haematology
#8
JOURNAL ARTICLE
Patrick Lawrence, Christina Brown
INTRODUCTION: There is an increasing research focus on the role of machine learning in the haematology laboratory, particularly in blood cell morphologic assessment. Human-level performance is an important baseline and goal for machine learning. This study aims to assess the interobserver variability and human-level performance in blood cell morphologic assessment. METHODS: A dataset of 1000 single white blood cell images were independently labelled by 10 doctors and morphology scientists...
October 6, 2024: European Journal of Haematology
#9
JOURNAL ARTICLE
Danilo De Novellis, Daniele Derudas, Donatella Vincelli, Raffaele Fontana, Roberta Della Pepa, Salvatore Palmieri, Fabrizio Accardi, Francesco Rotondo, Emanuela Morelli, Emilia Gigliotta, Daniela Roccotelli, Luana Marano, Maria Lucia Barone, Giusy Cetani, Daniela Esposito, Antonio Lazzaro, Giuseppe Delle Cave, Bianca Serio, Denise Morini, Marika Porrazzo, Eleonora Urciuoli, Chiara Masucci, Fulvia Fanelli, Michela Rizzo, Manuela Arcamone, Fabio Trastulli, Stefano Rocco, Aldo Leone, Rosario Bianco, Flavia Salvatore, Aurora Idato, Maria Sicari, Patrizia Tosi, Maria Gabriella Rascato, Maria Di Perna, Antonietta Pia Falcone, Lucia Morello, Melania Carlisi, Gino Svanera, Mario Annunziata, Ferdinando Frigeri, Catello Califano, Angelo Michele Carella, Gianpaolo Marcacci, Fabrizio Pane, Antonio Maria Risitano, Valentina Giudice, Ciro Botta, Carmine Selleri
Isatuximab, a novel anti-CD38 monoclonal antibody, is approved in combination with carfilzomib and dexamethasone (Isa-Kd) in relapsed/refractory multiple myeloma (RRMM) patients. Because of its recent introduction, real-world efficacy and safety are poorly reported. In this Italian multicenter real-life observational retrospective study, efficacy and safety of the Isa-Kd regimen were evaluated in a cohort of 103 RRMM patients. Overall response rate (ORR) was 85%, with stringent (sCR) or complete response (CR) in 18% of cases and very good partial response (VGPR) in 39%...
October 6, 2024: European Journal of Haematology
#10
REVIEW
Parul Gupta, Ravindra Kumar
Sickle cell disease (SCD) is a hereditary disorder characterized by vaso-occlusion, inflammation, and tissue damage. Intercellular adhesion molecule 1 (ICAM-1) plays a crucial role in the pathophysiology of SCD by promoting the adhesion of sickle cells to the endothelium, contributing to vaso-occlusion and tissue damage. The ICAM-1 gene encodes a glycoprotein that interacts with lymphocyte function-associated antigen 1 (LFA-1) and macrophage 1-antigen (Mac-1) receptors, perpetuating inflammation, and oxidative stress...
October 1, 2024: European Journal of Haematology
#11
JOURNAL ARTICLE
Graeme F Murray, Ian M Bouligny, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan A Wages, Steven Grant, Keri R Maher
Clonal evolution (CE) is a driving force behind the development and progression of acute myeloid leukemia (AML). Advances in molecular and cytogenetic assays have improved the depth and breadth of detection of CE in AML, which is defined here as a detected change in cytogenetic or molecular profile at relapsed or refractory (RR) disease. In this study, we demonstrate the clinical impact of CE in a cohort of patients with RR AML treated between 2013 and 2023. We discovered CE is significantly more frequent in relapsed disease (58...
September 24, 2024: European Journal of Haematology
#12
JOURNAL ARTICLE
Matteo Guerra, Emily Alouani, Thomas Hueso, Kaissa Ouali, Alina Danu, Antoine Hollebecque, Rastislav Bahleda, Christophe Willekens, Anas Gazzah, Capucine Baldini, Sophie Postel-Vinay, Jean-Baptiste Micol, Christophe Massard, Stéphane De Botton, Vincent Ribrag, Jean-Marie Michot
BACKGROUND: Early-phases clinical trials (Phases 1 and 2) have evolved from a traditional assessment of toxicity to an adaptive approach based on patients' medical needs and access to effective new therapies. The global risks, benefits, and relevance of early-phases clinical trials participation for patients with hematological malignancies remain poorly evaluated. PATIENTS AND METHODS: All early-phases clinical trials participations for patients with hematological malignancies, from 2008 to 2023, in a tertiary academic center in Europe, were reviewed...
September 21, 2024: European Journal of Haematology
#13
JOURNAL ARTICLE
Normann Steiner, Radwan Massoud, Johanna Richter, Tetiana Perekhrestenko, Nico Gagelmann, Christian Niederwieser, Kristin Rathje, Iryna Lastovytska, Mathias Schäfersküpper, Silke Heidenreich, Ina Rudolph, Gaby Zeck, Dietlinde Janson, Christine Wolschke, Francis Ayuketang Ayuk, Evgeny Klyuchnikov, Nicolaus Kröger
BACKGROUND: The optimal TBI dose for ALL patients undergoing allogeneic SCT is still not clearly defined. METHODS: Single-center retrospective analysis of high-risk ALL patients in CR1 treated with 8 Gy (n = 22) or 12 Gy (n = 50) TBI in combination with fludarabine and PTCy. Median patient age in the 8 Gy TBI cohort was 63 (37-79) and 37 (18-56) in the 12 Gy TBI cohort and median follow-up time was 21 months (range 1-92)...
September 19, 2024: European Journal of Haematology
#14
JOURNAL ARTICLE
Anne Birthe Helweg Jensen, Helene Riis Pontoppidan Andersen, Sarah Thorius Jensen, Christina Friis Jensen, Jesper Amstrup, René Mathiasen, Kasper Amund Henriksen, Henrik Hasle, Michael Thude Callesen, Ninna Brix
OBJECTIVES: Childhood cancer often presents with non-specific signs and symptoms that might mimic non-malignant disorders including musculoskeletal diseases, potentially leading to rheumatic and orthopaedic misdiagnoses. We aimed to compare clinical presentation, diagnostic interval and survival in paediatric acute myeloid leukaemia (AML) with and without initial musculoskeletal symptoms. METHODS: This nationwide retrospective, cohort study reviewed medical records of 144 children below 15 years diagnosed with AML in Denmark from 1996 to 2018...
September 18, 2024: European Journal of Haematology
#15
JOURNAL ARTICLE
Camilla Mazzoni, Lisa Argnani, Beatrice Casadei, Alessandro Broccoli, Giulia Gabrielli, Nicole Fabbri, Gabriele Gugliotta, Cinzia Pellegrini, Matteo Carella, Gianmarco Bagnato, Marianna Gentilini, Alice Morigi, Pierluca Maglio, Martina Cantelli, Vittorio Stefoni, Pier Luigi Zinzani
First-line therapy for patients with extranodal marginal zone lymphoma (EMZL) is not well established, except for eradication therapy for Helicobacter pylori in early gastric MZL. Various regimens, for example, locoregional treatment and systemic chemo-immunotherapy, can be used depending on the site and stage of disease. Single-agent rituximab is a useful approach in the setting of localized, low-intermediate risk EMZL. The aim our research was to analyze the effectiveness and safety of single-agent rituximab (375 mg/m2 once weekly for 4 weeks) in naïve EMZL in a real-life setting...
September 18, 2024: European Journal of Haematology
#16
JOURNAL ARTICLE
Yuelian Sun, Katalin Veres, Hans Carl Hasselbalch, Henrik Frederiksen, Lene Sofie Granfeldt Østgård, Erzsébet Horváth-Puhó, Victor W Henderson, Henrik Toft Sørensen
No abstract text is available yet for this article.
September 16, 2024: European Journal of Haematology
#17
JOURNAL ARTICLE
C Bucelli, I Capodanno, M C Miggiano, F Cavazzini, S Leonetti Crescenzi, S Russo, I Carmosino, M Annunziata, F Sorà, M Bonifacio, L Luciano, G Caocci, G Loglisci, C Elena, F Lunghi, R Mullai, I Attolico, G Binotto, E Crisà, P Sportoletti, A Di Veroli, A R Scortechini, A P Leporace, A Maggi, M Crugnola, F Stagno, R Sancetta, P Murgano, D Rapezzi, D Luzi, D I Vincelli, S Galimberti, M Bocchia, C Fava, A Malato, E Abruzzese, G Saglio, G Specchia, M Breccia, A Iurlo, M Tiribelli, R Latagliata
OBJECTIVES: The study aimed to evaluate the utilization of frontline TKI therapy in a large cohort of elderly CP-CML patients. METHODS: A retrospective analysis was conducted on 332 CP-CML patients aged 75 years or older among 1929 diagnosed from January 2012 to December 2019 followed at 36 participating Hematology Centers involved in the "Campus CML" project. RESULTS: Among the patients analyzed, 85.8% received imatinib (IM) while 14...
September 12, 2024: European Journal of Haematology
#18
JOURNAL ARTICLE
Jelena Jelicic, Karen Juul-Jensen, Zoran Bukumiric, Mikkel Runason Simonsen, Michael Roost Clausen, Ahmed Ludvigsen Al-Mashhadi, Robert Schou Pedersen, Christian Bjørn Poulsen, Anne Ortved Gang, Peter Brown, Tarec Christoffer El-Galaly, Thomas Stauffer Larsen
OBJECTIVES: Recent front-line clinical trials used the International Prognostic Index (IPI) to identify trial-eligible patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). However, many IPI-like variants with improved accuracy have been developed over the years for rituximab-treated patients. METHODS: We assessed the impact of International Prognostic Indices on patient enrolment in clinical trials, aiming to exclude low-risk IPI patients based on POLARIX/EPCORE DLBCL-2 trial criteria...
September 10, 2024: European Journal of Haematology
#19
JOURNAL ARTICLE
Kai Wille, Marvin Dumke, Nadine Wilsdorf, Parvis Sadjadian, Artur Schneider, Stephanie Jender-Bartling, Vera Kolatzki, Anette Horstmann, Raphael Meixner, Marina Jiménez-Muñoz, Christiane Fuchs, Hans-Joachim Tischler, Martin Griesshammer
INTRODUCTION: The prognosis of patients with refractory or relapsed AML (R/R-AML) is very limited. To (re)achieve complete remission, there has recently been increasing evidence that the combination of venetoclax (VEN) with chemotherapy is associated with improved outcomes. PATIENTS AND METHODS: Our retrospective, single-center study of 53 R/R-AML patients with a median follow-up time of 11.0 months compared standard salvage chemotherapy (FLAG-Ida or HAM in n = 35 patients) with a combination of venetoclax (VEN) and FLAG-Ida (FLAVIDA in n = 18 patients) concerning safety and efficacy...
September 9, 2024: European Journal of Haematology
#20
JOURNAL ARTICLE
Chie Ishikawa, Naoki Mori
OBJECTIVES: The role of glycogen synthase kinase (GSK)-3β in adult T-cell leukemia (ATL) caused by human T-cell leukemia virus type 1 (HTLV-1) is paradoxical and enigmatic. Here, we investigated the role of GSK-3β and its potential as a therapeutic target for ATL. METHODS: Cell proliferation/survival, cell cycle, apoptosis, and reactive oxygen species (ROS) generation were examined using the WST-8 assay, flow cytometry, and Hoechst 33342 staining, respectively...
September 6, 2024: European Journal of Haematology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
